Dr Tracy Dudding

Dr Tracy Dudding

Conjoint Senior Lecturer

School of Medicine and Public Health (Medical Genetics)

Career Summary

Biography

Dr Tracy Dudding-Byth is a full-time senior consultant clinical geneticist and an early career researcher in the field of rare genetic diseases, obtaining her PhD in 2012. She is a Chief Investigator within the University of Newcastle Grow-up-well Priority Research Centre and a founding co-director of Rare Voices Australia, a national advocacy organisation uniting the estimated 1.5 million Australians living with a rare disease.  

Dr Dudding-Byth joined the NSW Genetics of learning disability (GoLD) service  (0.6FTE) 2 years ago and continues to work 0.4FTE in the HNEhealth general genetic service. The NSW GOLD service is a nationally and internationally recognised clinical research service which has ascertained and clinically characterised over 200 families, each with an inherited form of intellectual disability for which the genetic basis remains unknown.

Publications: Research output includes 33 publications (11 first or senior author) and 1 PhD Thesis. This includes 1 Nature and 2 Nature Genetics publications as part of the KConFab consortium. Citation index:14

Contribution to field of research: As a clinical researcher, Dr Dudding-Byth has phenotypically and molecularly characterised a novel form of intellectual disability (Omim 117360) (Dudding et al., Neurology 2004; Huang et al Orphanet J Rare dis. 2012) and a novel form of oesophageal achalasia (Dudding et al., 2010 Clin Genet). She has extended the phenotypic characterisation of four genetic causes of intellectual disability. Her work exploring the relationship between inherited thrombophilia and adverse pregnancy outcome (Dudding et al., Thrombosis and Haemostasis 2004; Dudding et al J Thrombosis and Haemostasis) is referenced within UptoDate: Inherited thrombophilia and pregnancy; Gene reviews- inherited thrombophilia; and in the British Journal of Haematology: clinical guidelines for the testing for inherited thrombophilia. 

International collaboration:The GOLD service has well established collaborations with the Max Planck institute, Germany and the Wellcome Trust Sanger Institute, England. Care4Rare collaboration led to the identification of the gene for SCA29. Dr Dudding-Byth is leading an innovative project with Professor Brian Lovell from The University of Queensland evaluating the use of 2D facial recognition technology for matching the gestalt of individuals with known and unknown syndromic forms of intellectual disability [Oral presentation HGSA conference August 2015]. 

Research Support: Chief Investigator on University of Newcastle Grow-Up-Well Priority Research Centre Grant 2015. HNEhealth 2015 Innovation Scholarship: " The faceDx Project: Matching the faces of individuals with undiagnosed syndromic intellectual disability".

Community engagement: Co-founding director of Rare Voices Australia.  Dr Dudding-Byth sits on the Medical Advisory Committee of the Steve Waugh Foundation, a charity for children with rare diseases. 

2013: Invited speaker: RCPA Pathology:Australasian Division 37th Annual Scientific Meeting. Orphan Diseases: Challenges, Costs and Opportunities
2015: RACGP invited manuscript submission: A Powerful team: the family physician advocating for patients with a rare disease.

Supervision and mentoring: Dr Dudding-Byth is supervising 3 higher degree students in the field of rare disease research. She supervises medical students during their year 5 Special Study Option to write and publish a first author medical case report. Awarded HCRF 2015 Research Mentor of the year. 


Qualifications

  • Doctor of Philosophy, University of Newcastle
  • Bachelor of Medicine, University of Newcastle

Keywords

  • 2D facial recognition technology in dysmorphology
  • clinical genetics
  • epidemiology
  • intellectual disability
  • medical genetics
  • rare disease patient advocacy
  • rare genetic diseases

Fields of Research

Code Description Percentage
110399 Clinical Sciences not elsewhere classified 40
111299 Oncology and Carcinogenesis not elsewhere classified 35
111799 Public Health and Health Services not elsewhere classified 25

Professional Experience

Membership

Dates Title Organisation / Department
1/01/2012 -  Founding Director Rare Voices Australia
Australia
1/01/2012 -  Medical Advisory Committee Steve Waugh Foundation - Australia Inc.

Professional appointment

Dates Title Organisation / Department
1/01/2013 -  Senior Staff Specialist Clinical Genetics Hunter Genetics, Hunter Area Health Service
Australia
1/01/2013 -  Senior Staff Specialist NSW GOLD Service Hunter Genetics, Hunter Area Health Service
Australia

Awards

Research Award

Year Award
1997 Hunter Area Health Service Career Development Fund
Hunter Area Health Service

Scholarship

Year Award
1997 World Health Organisation (WHO) Travelling Scholarship
World Health Organisation
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Journal article (43 outputs)

Year Citation Altmetrics Link
2017 Le Fevre A, Beygo J, Silveira C, Kamien B, Clayton-Smith J, Colley A, et al., 'Atypical Angelman syndrome due to a mosaic imprinting defect: Case reports and review of the literature', American Journal of Medical Genetics, Part A, 173 753-757 (2017) [C1]

© 2017 Wiley Periodicals, Inc. Angelman syndrome (AS) is characterized by severe intellectual disability, limited, or absent speech and a generally happy demeanor. The four known... [more]

© 2017 Wiley Periodicals, Inc. Angelman syndrome (AS) is characterized by severe intellectual disability, limited, or absent speech and a generally happy demeanor. The four known etiological mechanisms; deletions, uniparental disomy, imprinting defects, and UBE3A mutation all affect expression of the UBE3A gene at 15q11-q13. An atypical phenotype is seen in individuals who are mosaic for a chromosome 15q11-q13 imprinting defect on the maternal allele. These patients present with a milder phenotype, often with hyperphagia and obesity or non-specific intellectual disability. Unlike typical AS syndrome, they can have a vocabulary up to 100 words and speak in sentences. Ataxia and seizures may not be present, and the majority of individuals do not have microcephaly. Here we review the current literature and present three individuals with atypical AS caused by a mosaic imprinting defect to demonstrate why DNA methylation analysis at the SNRPN locus needs to be considered in a broader clinical context. © 2017 Wiley Periodicals, Inc.

DOI 10.1002/ajmg.a.38072
Citations Scopus - 1Web of Science - 1
Co-authors T Dudding
2016 Kamien B, Dadd T, Buckman M, Ronan A, Dudding T, Meldrum C, et al., 'Somatic-Gonadal Mosaicism Causing Sotos Syndrome', AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 170 3360-3362 (2016)
DOI 10.1002/ajmg.a.37867
Co-authors Rodney Scott, T Dudding
2016 McInerney-Leo AM, Harris JE, Gattas M, Peach EE, Sinnott S, Dudding-Byth T, et al., 'Fryns Syndrome Associated with Recessive Mutations in PIGN in two Separate Families', Human Mutation, 37 695-702 (2016) [C1]

© 2016 WILEY PERIODICALS, INC. Fryns syndrome is an autosomal recessive condition characterized by congenital diaphragmatic hernia (CDH), dysmorphic facial features, distal digit... [more]

© 2016 WILEY PERIODICALS, INC. Fryns syndrome is an autosomal recessive condition characterized by congenital diaphragmatic hernia (CDH), dysmorphic facial features, distal digital hypoplasia, and other associated malformations, and is the most common syndromic form of CDH. No gene has been associated with this condition. Whole-exome sequence data from two siblings and three unrelated individuals with Fryns syndrome were filtered for rare, good quality, coding mutations fitting a recessive inheritance model. Compound heterozygous mutations in PIGN were identified in the siblings, with appropriate parental segregation: a novel STOP mutation (c.1966C > T: p.Glu656X) and a rare (minor allele frequency < 0.001) donor splice site mutation (c.1674+1G > C) causing skipping of exon 18 and utilization of a cryptic acceptor site in exon 19. A further novel homozygous STOP mutation in PIGN (c.694A > T: p.Lys232X) was detected in one unrelated case. All three variants affected highly conserved bases. The two remaining cases were negative for PIGN mutations. Mutations in PIGN have been reported in cases with multiple congenital anomalies, including one case with syndromic CDH. Fryns syndrome can be caused by recessive mutations in PIGN. Whether PIGN affects other syndromic and non-syndromic forms of CDH warrants investigation.

DOI 10.1002/humu.22994
Citations Scopus - 6Web of Science - 8
Co-authors T Dudding
2016 Petrovski S, Kury S, Myers CT, Anyane-Yeboa K, Cogne B, Bialer M, et al., 'Germline De Novo Mutations in GNB1 Cause Severe Neurodevelopmental Disability, Hypotonia, and Seizures', AMERICAN JOURNAL OF HUMAN GENETICS, 98 1001-1010 (2016) [C1]
DOI 10.1016/j.ajhg.2016.03.011
Citations Scopus - 8Web of Science - 8
Co-authors T Dudding
2016 Hwang YT, Dudding T, Mabel Aliaga S, Arpone M, Francis D, Li X, et al., 'Molecular Inconsistencies in a Fragile X Male with Early Onset Ataxia', GENES, 7 (2016)
DOI 10.3390/genes7090068
Citations Web of Science - 1
Co-authors T Dudding
2015 Oegema R, Cushion TD, Phelps IG, Chung SK, Dempsey JC, Collins S, et al., 'Recognizable cerebellar dysplasia associated with mutations in multiple tubulin genes', Human Molecular Genetics, 24 5313-5325 (2015) [C1]

© The Author 2015. Published by Oxford University Press. All rights reserved. Mutations in alpha- and beta-tubulins are increasingly recognized as a major cause of malformations ... [more]

© The Author 2015. Published by Oxford University Press. All rights reserved. Mutations in alpha- and beta-tubulins are increasingly recognized as a major cause of malformations of cortical development (MCD), typically lissencephaly, pachygyria and polymicrogyria; however, sequencing tubulin genes in large cohorts of MCD patients has detected tubulin mutations in only 1-13%. We identified patients with a highly characteristic cerebellar dysplasia but without lissencephaly, pachygyria and polymicrogyria typically associated with tubulin mutations. Remarkably, in seven of nine patients (78%), targeted sequencing revealed mutations in three different tubulin genes (TUBA1A, TUBB2B and TUBB3), occurring de novo or inherited from a mosaic parent. Careful re-review of the cortical phenotype on brain imaging revealed only an irregular pattern of gyri and sulci, for which we propose the term tubulinopathy-related dysgyria. Basal ganglia (100%) and brainstem dysplasia (80%) were common features. On the basis of in silico structural predictions, the mutations affect amino acids in diverse regions of the alpha-/beta-tubulin heterodimer, including the nucleotide binding pocket. Cell-based assays of tubulin dynamics reveal various effects of the mutations on incorporation into microtubules: TUBB3 p. Glu288Lys and p. Pro357Leu do not incorporate into microtubules at all, whereas TUBB2B p. Gly13Ala shows reduced incorporation and TUBA1A p. Arg214His incorporates fully, but at a slower rate than wild-type. The broad range of effects on microtubule incorporation is at odds with the highly stereotypical clinical phenotype, supporting differential roles for the three tubulin genes involved. Identifying this highly characteristic phenotype is important due to the low recurrence risk compared with the other (recessive) cerebellar dysplasias and the apparent lack of non-neurological medical issues.

DOI 10.1093/hmg/ddv250
Citations Scopus - 10Web of Science - 8
Co-authors T Dudding
2015 Dudding-Byth T, 'A powerful team: The family physician advocating for patients with a rare disease', AUSTRALIAN FAMILY PHYSICIAN, 44 634-638 (2015) [C1]
Citations Scopus - 3Web of Science - 3
Co-authors T Dudding
2015 Kamien B, Digilio MC, Novelli A, O'Donnell S, Bain N, Meldrum C, et al., 'Narrowing the critical region for overgrowth within 13q14.2-q14.3 microdeletions', European Journal of Medical Genetics, 58 629-633 (2015) [C3]

© 2015 Published by Elsevier Masson SAS. Large chromosomal deletions from 13q13.3 to 13q21.3 have previously been associated with overgrowth. We present two patients with deletio... [more]

© 2015 Published by Elsevier Masson SAS. Large chromosomal deletions from 13q13.3 to 13q21.3 have previously been associated with overgrowth. We present two patients with deletions at 13q14.2q14.3 who have macrocephaly, tall stature relative to their parents, cardiac phenotypes, and intellectual disability. This report narrows the critical region for tall stature, macrocephaly, and possibly cardiac disease. Crown

DOI 10.1016/j.ejmg.2015.10.006
Citations Scopus - 2Web of Science - 1
Co-authors Rodney Scott, T Dudding
2015 Corbett MA, Dudding-Byth T, Crock PA, Botta E, Christie LM, Nardo T, et al., 'A novel X-linked trichothiodystrophy associated with a nonsense mutation in RNF113A', Journal of Medical Genetics, 52 269-274 (2015) [C1]

Background: Trichothiodystrophy (TTD) is a group of rare autosomal recessive disorders that variably affect a wide range of organs derived from the neuroectoderm. The key diagnost... [more]

Background: Trichothiodystrophy (TTD) is a group of rare autosomal recessive disorders that variably affect a wide range of organs derived from the neuroectoderm. The key diagnostic feature is sparse, brittle, sulfur deficient hair that has a 'tiger-tail' banding pattern under polarising light microscopy. Patients and methods: We describe two male cousins affected by TTD associated with microcephaly, profound intellectual disability, sparse brittle hair, aged appearance, short stature, facial dysmorphism, seizures, an immunoglobulin deficiency, multiple endocrine abnormalities, cerebellar hypoplasia and partial absence of the corpus callosum, in the absence of cellular photosensitivity and ichthyosis. Obligate female carriers showed 100% skewed X-chromosome inactivation. Linkage analysis and Sanger sequencing of 737 X-chromosome exons and whole exome sequencing was used to find the responsible gene and mutation. Results: Linkage analysis localised the disease allele to a 7.75 Mb interval from Xq23-q25. We identified a nonsense mutation in the highly conserved RNF113A gene (c.901 C > T, p.Q301*). The mutation segregated with the disease in the family and was not observed in over 100 000 control X chromosomes. The mutation markedly reduced RNF113A protein expression in extracts from lymphoblastoid cell lines derived from the affected individuals. Conclusions: The association of RNF113A mutation with non-photosensitive TTD identifies a new locus for these disorders on the X chromosome. The extended phenotype within this family includes panhypopituitarism, cutis marmorata and congenital short oesophagus.

DOI 10.1136/jmedgenet-2014-102418
Citations Scopus - 6Web of Science - 6
Co-authors A Hackett, T Dudding
2015 van Kogelenberg M, Clark AR, Jenkins Z, Morgan T, Anandan A, Sawyer GM, et al., 'Diverse phenotypic consequences of mutations affecting the C-terminus of FLNA', JOURNAL OF MOLECULAR MEDICINE-JMM, 93 773-782 (2015) [C1]
DOI 10.1007/s00109-015-1261-7
Citations Web of Science - 2
Co-authors T Dudding
2013 Goel H, Dudding T, 'Carbimazole/Methimazole Embryopathy in Siblings: A Possible Genetic Susceptibility', BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY, 97 755-758 (2013)
DOI 10.1002/bdra.23200
Citations Scopus - 5Web of Science - 2
Co-authors T Dudding
2012 Dudding TE, Attia JR, 'Maternal factor V Leiden and adverse pregnancy outcome: Deciding whether or not to test', Journal of Maternal-Fetal & Neonatal Medicine, 25 889-894 (2012) [C1]
Citations Scopus - 4Web of Science - 2
Co-authors John Attia, T Dudding
2012 Huang L, Chardon JW, Carter MT, Friend KL, Dudding TE, Schwartzentruber J, et al., 'Missense mutations in ITPR1 cause autosomal dominant congenital nonprogressive spinocerebellar ataxia', Orphanet Journal of Rare Diseases, 7 (2012) [C1]
DOI 10.1186/1750-1172-7-67
Citations Scopus - 46Web of Science - 43
Co-authors Peter Schofield, T Dudding
2011 Vilain RE, Dudding TE, Braye SG, Groombridge C, Meldrum C, Spigelman AD, et al., 'Can a familial gastrointestinal tumour syndrome be allelic with Waardenburg syndrome?', Clinical Genetics, 79 554-560 (2011) [C3]
DOI 10.1111/j.1399-0004.2010.01489.x
Citations Scopus - 9Web of Science - 7
Co-authors T Dudding, Rodney Scott, Leonie Ashman, Stephen Ackland
2010 Zilliacus E, Meiser B, Lobb E, Dudding TE, Barlow-Stewart K, Tucker K, 'The virtual consultation: Practitioners' experiences of genetic counseling by videoconferencing in Australia', Telemedicine Journal and E-Health, 16 350-357 (2010) [C1]
DOI 10.1089/tmj.2009.0108
Citations Scopus - 17Web of Science - 16
Co-authors T Dudding
2010 Dudding TE, Lawrence O, Winship I, Froyen G, Vandewalle J, Scott R, Shelling AN, 'Array comparative genomic hybridization for the detection of submicroscopic copy number variations of the X chromosome in women with premature ovarian failure', Human Reproduction, 25 3159-3160 (2010) [C3]
Citations Scopus - 14Web of Science - 10
Co-authors Rodney Scott, T Dudding
2010 Truong HT, Dudding TE, Blanchard CL, Elsea SH, 'Frameshift mutation hotspot identified in Smith-Magenis syndrome: case report and review of literature', BMC Medical Genetics, 11 1-5 (2010) [C3]
Citations Scopus - 15Web of Science - 13
Co-authors T Dudding
2008 Winship IM, Dudding TE, 'Lessons from the skin: Cutaneous features of familial cancer', Lancet Oncology, 9 462-472 (2008) [C1]
DOI 10.1016/S1470-2045(08)70126-8
Citations Scopus - 32Web of Science - 26
Co-authors T Dudding
2008 Dudding TE, Heron J, Thakkinstian A, Nurk E, Golding J, Pembrey M, et al., 'Factor V Leiden is associated with pre-eclampsia but not with fetal growth restriction: A genetic association study and meta-analysis', Journal of Thrombosis and Haemostasis, 6 1868-1875 (2008) [C1]
DOI 10.111/j.1538-7836.2008.03134.x
Citations Scopus - 39Web of Science - 7
Co-authors T Dudding, Rodney Scott, John Attia
2008 Wakefield CE, Meiser B, Homewood J, Taylor A, Gleeson M, Williams R, et al., 'A randomized trial of a breast/ovarian cancer genetic testing decision aid used as a communication aid during genetic counseling', Psycho-Oncology, 17 844-854 (2008)

Objectives: To evaluate the impact of a decision aid for women considering genetic testing for breast/ovarian cancer risk given during genetic counseling. Methods: One hundred and... [more]

Objectives: To evaluate the impact of a decision aid for women considering genetic testing for breast/ovarian cancer risk given during genetic counseling. Methods: One hundred and forty-eight women were randomized to receive the decision aid or a control pamphlet at the beginning of their first consultation with a genetic counselor. When the patient received the decision aid, it was used to complement consultation discussions about genetic testing. One hundred and ten (74.3%) women completed the first questionnaire designed to elicit information about women's levels of decisional conflict and knowledge about genetic testing. Of these, 105 (70.9%) completed a second questionnaire to assess longer-term outcomes, 6 months postconsultation. Results: Results showed that women who received the decision aid felt more informed about genetic testing (¿ 2 (1) = 8.69; P = 0.003), had clearer values (¿ 2 (1) = 6.90; P = 0.009) and had higher knowledge levels (¿ 2 (2) = 6.49; P = 0.039) than women who received the control pamphlet. Conclusions: The developed decision aid improved patient outcomes better than a control pamphlet when implemented during genetic counseling and given to the patient to take home. Copyright © 2008 John Wiley & Sons, Ltd.

DOI 10.1002/pon.1353
Citations Scopus - 23
Co-authors T Dudding
2008 Ronan A, Buiting K, Dudding TE, 'Atypical Angelman syndrome with macrocephaly due to a familial imprinting center deletion', American Journal of Medical Genetics Part A, 146A 78-82 (2008) [C1]
DOI 10.1002/ajmg.a.31952
Citations Scopus - 5Web of Science - 6
Co-authors T Dudding
2008 Wakefield CE, Meiser B, Homewood J, Peate M, Taylor A, Lobb E, et al., 'A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk', Breast Cancer Research and Treatment, 107 289-301 (2008)

Purpose: To measure the effectiveness of a tailored decision aid (DA) designed to help women make informed decisions about genetic testing for breast/ovarian cancer risk. Methods:... [more]

Purpose: To measure the effectiveness of a tailored decision aid (DA) designed to help women make informed decisions about genetic testing for breast/ovarian cancer risk. Methods: A total of 145 women were randomized to receive the DA or a control pamphlet at the end of their first genetic counseling consultation. Of these, 120 (82.8%) completed two questionnaires, 1 week and 6 months post-consultation. Results: While the DA had no effect on informed choice, post-decisional regret or actual genetic testing decision, the trial showed that women who received the DA had higher knowledge levels and felt more informed about genetic testing than women who received the control pamphlet (¿ 2 (2) = 6.82; P = 0.033; ¿ 2 (1) = 4.86; P = 0.028 respectively). The DA also helped women who did not have blood drawn at their first consultation to clarify their values with regards to genetic testing (¿ 2 (1) = 5.27; P = 0.022). Women who received the DA were less likely to share the information with other family members than women in the control condition (¿ 2 (1) = 8.78; P = 0.003). Conclusions: Decision aids are an effective decision-support strategy for women considering genetic testing for breast/ovarian cancer risk, and are most effective before the patient has made a decision, which is generally at the point of having blood drawn. © 2007 Springer Science+Business Media, LLC.

DOI 10.1007/s10549-007-9539-2
Citations Scopus - 39
Co-authors T Dudding
2008 Wakefield CE, Spigelman A, 'Randomized trial of a decision aid for individuals considering genetic testing for hereditary nonpolyposis colorectal cancer risk', Cancer, 113 956-965 (2008) [C1]
Citations Scopus - 31Web of Science - 28
Co-authors T Dudding
2007 Easton DF, Search Collaborators Including, Forbes JF, 'Genome-wide association study identifies novel breast cancer susceptibility loci', Nature, 447 1087-1093 (2007) [C1]
DOI 10.1038/nature05887
Citations Scopus - 1573
Co-authors John Forbes, Rodney Scott, T Dudding
2006 Yoland A, John R, Mary-Anne Y, Judy K, Katherine T, Tarli B, et al., 'Risk-reducing surgery in women with familial susceptibility for breast and /or ovarian cancer', European Journal of Cancer, 42 621-628 (2006) [C1]
DOI 10.1016/j.ejca.2005.11.020
Citations Scopus - 30Web of Science - 30
Co-authors T Dudding
2006 Antill YC, Reynolds J, Young MA, Kirk JA, Tucker KM, Bogtstra TL, et al., 'Screening behavior in women at increased familial risk for breast cancer', Familial Cancer, 5 359-368 (2006) [C1]
DOI 10.1007/s10689-006-0006-8
Citations Scopus - 28Web of Science - 27
Co-authors T Dudding
2006 Tiller K, Meiser B, Gaff C, Kirk J, Dudding TE, Phillips KA, et al., 'A randomized controlled trial of a decision aid for women at increased risk of ovarian cancer', Medical Decision Making, 26 360-372 (2006) [C1]
DOI 10.1177/0272989X06290486
Citations Scopus - 21Web of Science - 18
Co-authors T Dudding
2006 Lobb EA, Butow PN, Moore A, Barratt A, Tucker K, Gaff C, et al., 'Development of a communication aid to facilitate risk communication in consultations with unaffected women from high risk breast cancer families: a pilot study', Journal of Genetic Counselling, 15 393-405 (2006) [C1]
DOI 10.1007/s10897-006-9023-x
Citations Scopus - 17
Co-authors T Dudding
2005 Lindqvist PG, Merlo J, Dudding T, Attia J, 'Rebuttal: Meta-analysis of the relationship of factor V Leiden and intrauterine growth restriction-based on solid evidence? (multiple letters) [6]', Thrombosis and Haemostasis, 94 230-232 (2005)
Co-authors T Dudding, John Attia
2005 Dudding T, Attia JR, 'Response to Rebuttal: Meta-analysis of the relationship of factor V Leiden and intrauterine growth restriction-based on solid evidence? (letter)', Thrombosis and Haemostasis, 94 230-232 (2005) [C3]
Co-authors T Dudding
2005 Lubinski J, Lynch HT, Schmutzler R, Brood-Van Zanten MMA, Van Der Mooren MJ, Verheijen RHM, et al., 'Hormone replacement therapy appears to be safe after prophylactic adnexectomy in premenopausal BRCA1/BRCA2 mutation carriers', Hereditary Cancer in Clinical Practice, 3 87-91 (2005)
Co-authors T Dudding
2005 Tiller K, Meiser B, Gould L, Tucker K, Dudding TE, Franklin J, et al., 'Knowledge of risk management strategies, and information and risk management preferences of women at increased risk for ovarian cancer', Psycho-Oncology, 14 249-261 (2005) [C1]
DOI 10.1002/pon.840
Citations Web of Science - 19
Co-authors T Dudding
2004 Dudding TE, Friend K, Schofield PW, Lee SJ, Wilkinson IA, Richards R, 'Autosomal dominant congenital non-progressive ataxia overlaps with the SCA15 locus', Neurology, 63 2288-2292 (2004) [C1]
DOI 10.1212/01.WNL.0000147299.80872.D1
Citations Scopus - 48Web of Science - 39
Co-authors T Dudding, Peter Schofield
2004 Attia J, Dudding T, Infante-Rivard C, 'The association between adverse pregnancy outcomes and maternal factor V Leiden genotype. a meta-analysis. (vol 91, pg 700, 2004)', THROMBOSIS AND HAEMOSTASIS, 92 434-434 (2004)
Citations Web of Science - 1
Co-authors T Dudding
2004 Attia JR, Dudding TE, Infante-Rivard C, 'Addendum to: The association between adverse pregnancy outcomes and maternal factor V Leiden genotype: A meta-analysis', Thrombosis and Haemostasis, 92 434 (2004) [C3]
Citations Scopus - 2
Co-authors John Attia, T Dudding
2004 Dudding TE, Attia JR, 'The association between adverse pregnancy outcomes and maternal factor V Leiden genotype: a meta-analysis', Journal of Thrombosis and Haemostasis, 91 700-711 (2004) [C2]
Citations Scopus - 105Web of Science - 81
Co-authors T Dudding, John Attia
2003 Groombridge C, Ingrey AJ, Gleeson M, Spigelman AD, Dudding TE, 'Factors influencing the dissemination of genetic information in families with an inherited predisposition to colorectal cancer', Familial Cancer, 2 69 (2003) [C3]
Co-authors T Dudding
2001 Meiser B, Butow P, Barratt A, Gattas M, Gaff C, Haan E, et al., 'Risk perceptions and knowledge of breast cancer genetics in women at increased risk of developing hereditary breast cancer', Psychology & Health, 16 297-311 (2001) [C1]
DOI 10.1080/08870440108405508
Citations Scopus - 33
Co-authors T Dudding
2000 Dudding TE, Wilcken B, Burgess BT, Turner G, 'Neonatal screening for cystic fibrosis', The Lancet, 356 1930 (2000) [C3]
Citations Scopus - 10
Co-authors T Dudding
2000 Dudding TE, Wilcken B, Burgess BT, Hambly J, Turner G, 'Reproductive decisions after neonatal screening identifies cystic fibrosis', Archives of Disease in Childhood (Fetal and Neonatal Edition), 82 F124-F127 (2000) [C1]
Citations Scopus - 41
Co-authors T Dudding
1998 Dudding TE, Rogers M, Roddick LG, Relic J, Edwards MJ, 'Nevoid hypertrichosis with multiple patches of hair that underwent almost complete spontaneous resolution', AMERICAN JOURNAL OF MEDICAL GENETICS, 79 195-196 (1998)
DOI 10.1002/(SICI)1096-8628(19980923)79:3&lt;195::AID-AJMG8&gt;3.0.CO;2-M
Citations Scopus - 8Web of Science - 5
Co-authors T Dudding
1998 Evans DGR, Hill J, Dudding T, Burn J, Maher ER, 'Molecular genetic tests in surgical management of familial adenomatous polyposis - reply', LANCET, 351 1131-1132 (1998)
DOI 10.1016/S0140-6736(05)79414-9
Citations Scopus - 6
Co-authors T Dudding
1997 Evans DGR, Hill J, Dudding TE, Burn J, Maher ER, 'Molecular genetic tests in surgical management of familial adenomatous polyposis', The Lancet, 350 1777 (1997) [C3]
DOI 10.1016/s0140-6736(05)63606-9
Citations Scopus - 13Web of Science - 10
Co-authors T Dudding
Show 40 more journal articles

Conference (5 outputs)

Year Citation Altmetrics Link
2005 McKenzie F, Dudding TE, Edwards MJ, Giles WB, Hackett AK, Somerset D, Woodford P, 'Review of late fetal loss in the Hunter and proposed strategies for investigation', Human Genetics Society of Australasia (2005) [E3]
Co-authors T Dudding, A Hackett
2004 McKenzie F, Dudding TE, Fagan KA, Edwards MJ, 'Subtelomere FISH in the Hunter', Conference Abstract (2004) [E3]
Co-authors T Dudding
2004 Dudding TE, Christie L, Crawford J, Gecz J, Turner G, 'The use of skewed maternal X inactivation in prenatal counselling', Conference Abstract (2004) [E3]
Co-authors T Dudding
2004 Antill Y, Dudding TE, Hall T, Kirk J, Reynolds J, Tucker K, et al., 'Breast and ovarian cancer screening practices and prophylactic surgery in at risk women: an Australian multicenter study', Poster Presentation (2004) [E3]
Co-authors T Dudding
2003 Spigelman AD, Gani JS, Burgess BT, Groombridge C, Dudding TE, Ingrey AJ, et al., 'Advanced Duodenal Polyposis: Literature review and experience with pancreas-sparing duodenectomy inpatients with familial adenomatous polyposis (FAP)', Familial Cancer (2003) [E4]
Co-authors Rodney Scott, T Dudding, Maree Gleeson
Show 2 more conferences
Edit

Grants and Funding

Summary

Number of grants 6
Total funding $1,612,000

Click on a grant title below to expand the full details for that specific grant.


20081 grants / $300,000

Platform technology capacity building grant: Consortium for the Inherited Renal Malignancies (CONFIRM)$300,000

Funding body: Victorian Cancer Agency

Funding body Victorian Cancer Agency
Project Team

Jenkins M,Southery M, Carrol, R, Bogwitz M, Goldar D, Dudding T, Tucker K.

Scheme Seed funding
Role Investigator
Funding Start 2008
Funding Finish 2009
GNo
Type Of Funding Aust Competitive - Non Commonwealth
Category 1NS
UON N

20062 grants / $1,017,000

Strategic research partnership grant$1,000,000

Funding body: Cancer Council NSW

Funding body Cancer Council NSW
Project Team

Meiser B, Lobb E, Tucker K, Andrews L, Kirk J, Friedlander M, Mireskandari S, Kasparian N, Wakefield C, Dudding T.

Scheme Project Grant
Role Investigator
Funding Start 2006
Funding Finish 2010
GNo
Type Of Funding Aust Competitive - Non Commonwealth
Category 1NS
UON N

The use of array based comparative genomic hybridization for the detection of sub-microscopic x-chromosomal abnormalities in women with premature ovarian failure$17,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Tracy Dudding, Conjoint Professor Gillian Turner
Scheme Project Grant
Role Lead
Funding Start 2006
Funding Finish 2006
GNo G0186095
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

20022 grants / $280,000

A Nested Case Control Study evaluating the association between the factor V Leiden genotype and adverse pregnancy outcome$165,000

Funding body: National Health and Medical Research Council

Funding body National Health and Medical Research Council
Project Team

Scott, R; Dudding-Byth, T.

Scheme Project Grant
Role Investigator
Funding Start 2002
Funding Finish 2004
GNo
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON N

A randomised trial of a decision aid for women at risk of ovarian cancer$115,000

Funding body: National Health and Medical Research Council

Funding body National Health and Medical Research Council
Project Team

Friedlander M, Tiller K, Kirk J, Gaff C. Associate investigators: Dudding-Byth T, Meiser B, Tucker K, Reeson L, Robertson G, Hammond.

Scheme Project Grant
Role Investigator
Funding Start 2002
Funding Finish 2002
GNo
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON N

20011 grants / $15,000

Congenital thrombophilia and adverse pregnancy outcome$15,000

Funding body: Charitable Trust

Funding body Charitable Trust
Scheme Seed funding
Role Lead
Funding Start 2001
Funding Finish 2001
GNo
Type Of Funding Not Known
Category UNKN
UON N
Edit

Research Supervision

Number of supervisions

Completed1
Current2

Total current UON EFTSL

Masters0.05
PhD0.1

Current Supervision

Commenced Level of Study Research Title Program Supervisor Type
2017 PhD The Genetics of Overgrowth Syndromes PhD (Medical Genetics), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2015 Masters An exploration of the diagnostic journey of children with Neuronal Ceroid Lipofuscinosis (NCL) M Philosophy (Nursing), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor

Past Supervision

Year Level of Study Research Title Program Supervisor Type
2017 PhD From General Developmental Disability to 22Q11.2 Deletion Syndrome: Understanding Parental Experiences PhD (Psychology - Science), Faculty of Science, The University of Newcastle Co-Supervisor
Edit

Research Collaborations

The map is a representation of a researchers co-authorship with collaborators across the globe. The map displays the number of publications against a country, where there is at least one co-author based in that country. Data is sourced from the University of Newcastle research publication management system (NURO) and may not fully represent the authors complete body of work.

Country Count of Publications
Australia 42
United Kingdom 11
Netherlands 5
United States 5
Germany 4
More...
Edit

Dr Tracy Dudding

Position

Conjoint Senior Lecturer
School of Medicine and Public Health
Faculty of Health and Medicine

Focus area

Medical Genetics

Contact Details

Email tracy.dudding@newcastle.edu.au
Phone (02) 4985 3100
Fax (02) 4925 3133

Office

Building Newcastle Western Suburbs Hospital
Location Other

,
Edit